title: Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus.
abstract: Respiratory syncytial virus (RSV) causes severe respiratory diseases in infants and young children. Inappropriate immunity to the virus can lead to disease enhancement upon subsequent infection. In this study, we have characterized the antiviral immunity elicited by the recombinant Semliki Forest virus (SFV) encoding the RSV fusion (F) and attachment (G) protein, and compared with that induced by the immune-stimulating complex (ISCOM)-incorporated FG proteins. Antiviral immunity against RSV elicited nasally or parentally by either of the immunogen having divergent profiles could reduce lung RSV titers upon challenge. However, resistance to RSV without disease enhancement was only observed in those vaccinated with SFV recombinants via nasal route. Presence of postvaccination pulmonary IFN-gamma response to the H-2K(d)-restricted T cell epitope (F(85-93); KYKNAVTEL) was found to be associated with absence of enhanced pulmonary disease and goblet cell hyperplasia as well as reduced Th2-cytokine expression. This result demonstrates that the SFV recombinants can result in enhanced clearance of RSV without enhancing the RSV-associated disease, and underlines the importance in priming pulmonary MHC class I-restricted T cells when RSV FG-based vaccines are used.
authors.affiliation: Microbiology and Tumorbiology Center, Karolinska Institutet, Stockholm, Sweden. Margaret.Chen@mtc.ki.se
authors.forename: Margaret
authors.initials: M
authors.lastname: Chen
authors.forename: Ke-Fei
authors.initials: KF
authors.lastname: Hu
authors.forename: Björn
authors.initials: B
authors.lastname: Rozell
authors.forename: Claes
authors.initials: C
authors.lastname: Orvell
authors.forename: Bror
authors.initials: B
authors.lastname: Morein
authors.forename: Peter
authors.initials: P
authors.lastname: Liljeström
mesh_terms: D000281:Administration, Intranasal; D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology / Q000821:virology; D016207:Cytokines / Q000096:biosynthesis; D016882:ISCOMs / Q000008:administration & dosage / Q000276:immunology*; D016056:Immunodominant Epitopes / Q000235:genetics / Q000276:immunology; D016130:Immunophenotyping; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis; D008168:Lung / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology* / Q000473:pathology / Q000821:virology; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012672:Semliki forest virus / Q000235:genetics / Q000276:immunology*; D013154:Spleen / Q000276:immunology / Q000378:metabolism / Q000821:virology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014760:Viral Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D016207:Cytokines; D016882:ISCOMs; D016056:Immunodominant Epitopes; D022261:Respiratory Syncytial Virus Vaccines; D014614:Vaccines, Synthetic; D014760:Viral Fusion Proteins; D014764:Viral Proteins; D007371:Interferon-gamma